ImageneBio, Inc. (IMA) Stock Price & Analysis
ImageneBio, Inc. (IMA) closed at USD 4.03 on Thursday, October 15, 2026, down 2.90% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 4.15; the Oct 15, 2026 session ranged USD 3.98–4.26 on volume of 21,319 shares. Market capitalization is $45.84M, with a 52-week range of USD 3.9–9.1 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:20 UTC.
Also available as compact Markdown for AI agents: nexqual.com/IMA.md
Key facts (IMA)
- Analysts: Hold (mean 2.50 on a 1–5 scale) (4 analysts), mean target USD 18 (range 2–28).
- Total return with dividends: 1Y -46.9% vs S&P 500 +18.1%; 5Y -97.2% vs S&P 500 +85.1%.
Analysts (IMA)
Consensus Hold (mean 2.50 on a 1–5 scale), 4 analysts; mean target USD 18 (low 2, high 28).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-21 | HC Wainwright & Co. | Initiated | Buy | $28 |
Total return (dividends reinvested) (IMA)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -46.9% | -97.2% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -47.0% | -51.1% |
| Volatility (annualized) | 56.7% | 95.1% |
| Max drawdown | -54.1% (Oct 2025→Oct 2026) | -98.0% (Nov 2021→Oct 2026) |
Key Statistics (as of October 16, 2026 at 05:20 UTC)
| Price | USD 4.03 |
|---|---|
| Change | ▼ 2.90% (down) |
| Previous Close | USD 4.15 |
| Open | USD 4.26 |
| Day Range | USD 3.98 – 4.26 |
| 52-Week Range | USD 3.9 – 9.1 |
| Volume | 21,319 shares |
| Market Cap | $45.84M |
| Exchange | NCM |
Technical Analysis (IMA)
Nexqual's technical model rates IMA "SELL" based on 3 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:20 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 19.04 (oversold) |
| vs SMA50 | Below (USD 5.03) |
| MACD | -0.25 (negative) |
Analyst Ratings (IMA)
Wall Street analysts rate IMA "Hold" based on 4 analysts, with a mean price target of USD 18 (range USD 2–28), per Nexqual as of October 16, 2026 at 05:20 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 18 |
| High Target | USD 28 |
| Low Target | USD 2 |
| Buy / Hold / Sell | 3 / 0 / 1 |
Earnings (IMA)
| EPS Estimate | USD -0.85 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.63 vs est -0.98 ▲ beat |
| 2026-03-31 | USD -0.95 vs est -0.66 ▼ miss |
| 2025-09-30 | USD -2.91 vs est -1 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financials & Fundamentals (IMA)
| Total Revenue | $0 |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -82.68% |
| Debt / Equity | 0.01 |
| Current Ratio | 21.47 |
| Total Cash | $136.15M |
| Total Debt | $1.91M |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financial Health Score (IMA)
Nexqual rates ImageneBio, Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:20 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $136M cash vs $2M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$53M (TTM) |
| Efficiency | Critical — ROE -83%, ROA -43.1% |
Ownership (IMA)
| Insider Ownership | +16.19% |
|---|---|
| Institutional Ownership | +54.59% |
| Shares Outstanding | 11.37M |
| Float | 5.83M |
| Short % of Float | +0.29% |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Leadership (IMA)
ImageneBio, Inc. is led by Kristin Yarema (age 54), CEO & Director, per Nexqual as of October 16, 2026 at 05:20 UTC.
| CEO & Director | Kristin Yarema (age 54) |
|---|---|
| CFO, Principal Financial Officer & Principal Accounting Officer | Yanina Grant-Huerta (age 48) |
| Chief Strategy & Operations Officer | Kurinji Pandiyan |
Major Backers & Investors (IMA)
Notable institutional backers of ImageneBio, Inc. include BVF Inc., Blue Owl Capital Holdings LP, Orbimed Advisors LLC., according to Nexqual as of October 16, 2026 at 05:20 UTC.
Active Investors
| Investor | Stake |
|---|---|
| BVF Inc. | 9.78% |
| Blue Owl Capital Holdings LP | 8.08% |
| Orbimed Advisors LLC. | 8.01% |
| Cable Car Capital, LP | 6.89% |
| Omega Fund Management, Llc | 4.01% |
| RTW Investments LP | 2.95% |
| Trails Edge Capital Partners, LP | 2.48% |
| BML Capital Management, LLC | 1.77% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 5.64% |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:20 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt